Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~

~ Executed Exclusive Licensing Agreement with Norgine to Commercialize PEDMARQSI™ in Europe, Australia, and New Zealand ~

~ Amended PEDMARK Permanent J-code 07901 Became Effective April 1, 2024 ~

~ Company Has Approximately $51 Million in Cash, Cash Equivalents, and Investment Securities ~

~ Management to Host Conference Call Today at 8:30 a.m. ET ~

RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2024, and provided a business update.

"We made significant progress with our strategic plans to refocus our organizational efforts in the outpatient oncology community where PEDMARK use has been endorsed by the NCCN in the adolescent and young adult (AYA) population. Effective April 1, CMS has amended our permanent J-code to specify the non-interchangeability of PEDMARK with other formulations of sodium thiosulfate (STS). With the successful execution of the Norgine EU licensing agreement, we are well funded and confident in the significant market opportunity in front of us," said Rosty Raykov, chief executive officer of Fennec Pharmaceuticals.

Recent Developments and Highlights:

  • Achieved PEDMARK net product revenue of approximately $7.4 million in the first quarter of 2024 and total net revenues of $25.4 million, which is inclusive of $18.0 million in revenue from the Norgine transaction.

  • Amended permanent J-Code, which became effective on April 1, 2024, now clearly specifies PEDMARK ® from other formulations of sodium thiosulfate (STS).

  • Announced execution of exclusive licensing agreement with Norgine to commercialize PEDMARQSI in Europe, Australia, and New Zealand. Fennec received approximately $43.2 million upfront and has the potential to receive up to approximately $230 million in additional commercial and regulatory milestones, and double-digit tiered royalties.

  • Within the first quarter, Fennec participated in eleven regional oncology conferences, as well as seven key scientific meetings, including the American Society of Pediatric Hematology/Oncology, the Community Oncology Alliance, the National Comprehensive Cancer Network, and the American Academy of Audiology annual conferences.

Financial Results for the First Quarter 2024

  • Net Sales – The company recorded net product sales of $7.4 million and $18.0 million in licensing revenue for total net sales of $25.4 million for the three-month period ended March 31, 2024, compared to $1.7 million in product sales and no licensing revenue for the same period in 2023. The Company recorded discounts and allowances against sales in the amount of $2.1 million and cost of products sold of $0.6 million for the three-month period ended March 31, 2024. For the same period in 2023, the Company recorded $0.2 million in discounts and allowances and $0.1 million in cost of goods sold.

  • Cash Position – Cash and cash equivalents were $51.2 million at March 31, 2024 and $13.3 million at December 31, 2023. The increase in cash and cash equivalents between March 31, 2024, and December 31, 2023, is the result of cash outlays for operating expenses related to the promotion of our product, selling and marketing expenses and general and administrative expenses, which were offset by cash inflows of approximately $43.2 million from the Norgine deal. We anticipate that our cash, cash equivalents and investment securities as of March 31, 2024 will be sufficient to fund our planned operations for at least the next twelve months.

  • Selling and Marketing Expenses –The Company recorded $5.2 million in selling and marketing expenses for the period ended March 31, 2024, compared to $2.5 million for the same period in 2023. The increase is largely related to increased headcount and additional marketing expenses in the comparable period.

  • General and Administrative (G&A) Expenses – G&A expenses increased by approximately $1.6 million over the same period in 2023 to $5.8 million. There was a significant increase in consulting, and professional costs related to European pre-commercialization related expenses in the 2024 period over the comparable period.

  • Net Earnings – Net income for the quarter ended March 31, 2024 was $12.8 million (basic EPS $0.47 per share, diluted EPS $0.41), compared to a net loss of $6.1 million (basic and diluted loss of $0.23 per share) for the same period in 2023.

Q1 2024 Conference Call Information

Date: Tuesday, May 14, 2024
Time: 8:30 a.m. ET
Link: https://register.vevent.com/register/BI137d97d6710341398d6f17d0433dc5b8

To access the conference call, please register using https://register.vevent.com/register/BI137d97d6710341398d6f17d0433dc5b8 . Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.

Financial Update

The selected financial data presented below is derived from our unaudited condensed consolidated financial statements, which were prepared in accordance with U.S. generally accepted accounting principles. The complete unaudited condensed consolidated financial statements for the period ended March 31, 2024 and management's discussion and analysis of financial condition and results of operations will be available via www.sec.gov and www.sedar.com. All values are presented in thousands unless otherwise noted.

Unaudited Condensed Consolidated
Statements of Operations
(U.S. Dollars in thousands except per share amounts)
Three Months Ended
March 31, March 31,
2024
2023
Revenue
PEDMARK product sales, net $ 7,419 $ 1,677
Licensing revenue 17,958
Total revenue 25,377 1,677
Operating expenses:
Cost of products sold 550 95
Research and development 3 4
Selling and marketing 5,209 2,531
General and administrative 5,872 4,317
Total operating expenses 11,634 6,947
Income/(loss) from operations 13,743 (5,270 )
Other (expense)/income
Unrealized foreign exchange loss (38 ) 9
Amortization expense (20 ) (72 )
Unrealized loss on securities (11 ) (30 )
Interest income 197 109
Interest expense (1,034 ) (798 )
Total other expense (906 ) (782 )
Net income/(loss) $ 12,837 $ (6,052 )
Basic net income/(loss) per common share $ 0.47 $ (0.23 )
Diluted net income/(loss) per common share $ 0.41 $ (0.23 )
Weighted-average number of common shares outstanding basic 27,090 26,559
Weighted-average number of common shares outstanding diluted 31,136 26,559


Fennec Pharmaceuticals Inc.
Balance Sheets
(U.S. Dollars in thousands)
Unaudited Audited
March 31, December 31,
2024 2023
Assets
Current assets
Cash and cash equivalents $ 51,184 $ 13,269
Accounts receivable, net 10,274 8,814
Prepaid expenses 4,488 2,575
Inventory 2,064 2,156
Other current assets 161 44
Total current assets 68,171 26,858
Non-current assets
Other non-current assets, net amortization 1,022 6
Total non-current assets 1,022 6
Total assets $ 69,193 $ 26,864
Liabilities and stockholders' deficit
Current liabilities:
Accounts payable $ 5,204 $ 3,778
Accrued liabilities 4,363 3,754
Operating lease liability - current 17 21
Contract liability - Norgine 252
Total current liabilities 9,836 7,553
Long term liabilities
Term loan 30,000 30,000
PIK interest 1,617 1,219
Debt discount (268 ) (288 )
Contract liability - Norgine 24,994 2
Total long term liabilities 56,343 30,933
Total liabilities 66,179 38,486
Stockholders' deficit:
Common stock, no par value; unlimited shares authorized; 27,105 shares issued and outstanding (2023 ‑27,027) 144,934 144,307
Additional paid-in capital 63,245 62,073
Accumulated deficit (206,408 ) (219,245 )
Accumulated other comprehensive income 1,243 1,243
Total stockholders' equity/(deficit) 3,014 (11,622 )
Total liabilities and stockholders' deficit $ 69,193 $ 26,864


Working Capital
Working capital Fiscal Period Ended
Selected Asset and Liability Data: March 31, 2024 December 31, 2023
(U.S. Dollars in thousands)
Cash and equivalents $ 51,184 $ 13,269
Other current assets 16,987 13,589
Current liabilities 9,836 7,553
Working capital $ 58,335 $ 19,305
Selected Equity:
Common stock and additional paid in capital 208,179 206,380
Accumulated deficit (206,408 ) (219,245 )
Stockholders' equity / (deficit) 3,014 (11,622 )

About Cisplatin-Induced Ototoxicity
Cisplatin and other platinum compounds are essential chemotherapeutic agents for the treatment of many pediatric malignancies. Unfortunately, platinum-based therapies can cause ototoxicity, or hearing loss, which is permanent, irreversible, and particularly harmful to the survivors of pediatric cancer. i

The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids or cochlear implants, which can be helpful for some, but do not reverse the hearing loss and can be costly over time. ii Infants and young children that are affected by ototoxicity at critical stages of development lack speech and language development and literacy, and older children and adolescents often lack social-emotional development and educational achievement. iii

PEDMARK ® (sodium thiosulfate injection)
PEDMARK ® is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. 7 PEDMARK is also the only therapeutic agent with proven efficacy and safety data with an established dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

In the U.S. and Europe, it is estimated that, annually, more than 10,000 children may receive platinum-based chemotherapy. The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult, and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.

PEDMARK has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Indications and Usage
PEDMARK ® (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Limitations of Use
The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.

Important Safety Information
PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.

Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.

PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.

Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium levels at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.

Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73m 2 .

Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.

The most common adverse reactions (≥25% with difference between arms of >5% compared to cisplatin alone) in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (≥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.

Please see full Prescribing Information for PEDMARK ® at: www.PEDMARK.com .

About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK ® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023. PEDMARK has received Orphan Drug Exclusivity in the U.S. For more information, please visit www.fennecpharma.com .

Forward Looking Statements
Except for historical information described in this press release, all other statements are forward-looking. Words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "may," "will," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about our business strategy, timeline and other goals, plans and prospects, including our commercialization plans respecting PEDMARK ® , the market opportunity for and market impact of PEDMARK ® , its potential impact on patients and anticipated benefits associated with its use, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, our ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2023. Fennec disclaims any obligation to update these forward-looking statements except as required by law.

For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com .

PEDMARK ® and Fennec ® are registered trademarks of Fennec Pharmaceuticals Inc.

©2024 Fennec Pharmaceuticals Inc. All rights reserved. FEN-1604-v1

For further information, please contact:

Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299

Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com

_________________________________

i Rybak L. Mechanisms of Cisplatin Ototoxicity and Progress in Otoprotection. Current Opinion in Otolaryngology & Head and Neck Surgery. 2007, Vol. 15: 364-369.
ii Landier W. Ototoxicity and Cancer Therapy. Cancer . June 2016 Vol. 122, No.11: 1647-1658.
iii Bass JK, Knight KR, Yock TI, et al. Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report from the Children's Oncology Group. Pediatric Blood & Cancer . 2016 Jul;63(7):1152-1162.



Primary Logo

News Provided by GlobeNewswire via QuoteMedia

FENC
The Conversation (0)
Patriot Expands High-Grade "Vega Zone" at CV13 with Multiple Drill Intercepts

Patriot Expands High-Grade "Vega Zone" at CV13 with Multiple Drill Intercepts

Highlights
  • Significant expansion to the recently discovered high-grade zone (herein termed the " Vega Zone ") at the CV13 Spodumene Pegmatite. Highlights include:
    • 33.4 m at 2.40% Li 2 O , including 11.1 m at 4.33% Li 2 O , and 17.6 m at 1.89% Li 2 O , including 5.6 m at 3.40% Li 2 O (CV24-507).
    • 43.2 m at 1.10% Li 2 O , including 12.9 m at 3.06% Li 2 O (CV24-498).
    • 27.1 m at 1.02% Li 2 O including 7.6 m at 2.39% Li 2 O (CV24-513).
    • 32.1 m at 0.78% Li 2 O , including 10.7 m at 2.17% Li 2 O (CV24-499).
  • Vega Zone is open in several directions with multiple step-out holes remaining to be reported.
    • High-grade mineralization is relatively flat-lying to shallow dipping and has now been delineated over a significant area and thickness.
  • Highest individual core sample assay reported to date at Corvette – 1.7 m at 7.01% Li 2 O (CV24–507, Vega Zone).
  • Along the western arm at CV13, mineralized pegmatite has been extended down-dip to over 400 m (~190 m vertical depth from surface) with intercepts including 13.5 m at 1.15% Li 2 O (CV24-497), and 8.6 m at 1.21% Li 2 O (CV24–518).
  • Results for 32,149 m (83 holes) remain to be reported from the 2024 winter drill program – 27,611 m (67 holes) at CV5, and 4,538 m (16 holes) at CV13.
  • The Vega Zone will be a key target for the upcoming summer drill program, with details of the program to be released to the market in the coming weeks.

June 11, 2024 Sydney, Australia

Patriot Battery Metals Inc. (the "Company" or "Patriot") (TSX: PMET) (ASX: PMT) (OTCQX: PMETF) (FSE: R9GA) is pleased to announce the next batch of core assay results from the CV13 Spodumene Pegmatite, including holes targeting the recently discovered high-grade zone (herein termed the "Vega Zone"), from its recently completed 2024 winter drill program at Corvette. The Corvette Property (the "Property" or "Project"), wholly owned by the Company, is located in the Eeyou Istchee James Bay region of Quebec . The CV13 Spodumene Pegmatite is located approximately 3 km west-southwest of the CV5 Spodumene Pegmatite, which hosts a maiden mineral resource estimate ("MRE") of 109.2 Mt at 1.42% Li 2 O inferred 1 and is situated approximately 13.5 km south of the regional and all–weather Trans-Taiga Road and powerline infrastructure.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Noble Minerals Plans to Drill in proximity to the Location of a 140 kg, Mineralized Boulder Found near Hearst, Ontario

Noble Minerals Plans to Drill in proximity to the Location of a 140 kg, Mineralized Boulder Found near Hearst, Ontario

(TheNewswire)

Noble Mineral Exploration Inc.

Toronto, Ontario TheNewswire - May 28, 2024 Noble Mineral Exploration Inc. ( "Noble" or the "Company" ) (TSXV:NOB ) ( FRANKFURT:NB7 ) ( OTCQB:NLPXF) is pleased to announce that the company has plans to execute a drill program on 214 claims in Way Township commencing in mid-Jine. The claims extend from about 4 to 15 km southwest of the town of Hearst, Ontario. The property area is equivalent to approximately 4,500 hectares or 45 sq km. The drill program follows geophysical surveys done to identify targets that may be the source of the mineralized boulder. The recent geophysical program was partially funded by the Ontario Junior Exploration Program and application has been made to the same program to fund the drill program. The Program will fund up to $200,000 on a $400,000 exploration program.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Drilling Dramatically Increases Strike Length of D-Vein with highs to 920 gpt Silver and 4.1% lead-zinc at Columba High-Grade Silver Project

Drilling Dramatically Increases Strike Length of D-Vein with highs to 920 gpt Silver and 4.1% lead-zinc at Columba High-Grade Silver Project

Kootenay Silver Inc. (TSXV: KTN) (the "Company" or "Kootenay") is very pleased to announce results from the first six drill holes targeting the eastern extension of the D-Vein target.

Kootenay Silver Inc. Logo (CNW Group/Kootenay Silver Inc.)

Four of the first six holes (CDH-24-148 to 151) were deliberately drilled at shallow levels to establish dip orientation of the vein before testing the deeper productive zone. Outcrop exposure is limited in the drilling area and initial holes drilled for structure followed by holes CDH-24-152 and 153 that drilled for grade at a significant 200 meter step out from previous intercepts at a comparable depth.

Holes CDH-24-152 and 153 targeted D-Vein at or below the important elevation of 1750 meters above sea level below which, as a rule of thumb at Columba Project, high silver grades are encountered. These two holes are on the same fence and are both very large step outs of 200 meters from the nearest intercept below 1750m elevation (CDH-23-147). and both intercepted mineralization in the  D-vein. The two holes are 150 meters apart in the dip direction.

Holes CDH-24-152 to 153 increase the previously established 450 meter strike length to 650 meters between holes CDH-23-136 to 137 and CDH-24-152 to 153.

Highlights

CDH-24-153

  • 435 gpt silver over 11 meters drilled width/3.52 meters estimated true width within 183 gpt silver over 40 meters drilled width/12.96 meters estimated true width
  • 920 gpt silver assay high over 1.35 meters drilled width/0.43 meters est. true width
  • Very large lateral step out along strike from nearest holes at similar elevation around 1600 to 1675m .
  • ~325 meters from CDH-23-145 (22 meters/15.4 meters est. true width of 174 gpt silver with 6 meters/4.2 meters est. true width of 435 gpt silver and 1 meter of 814 gpt silver ) 1
  • ~375 meters from CDH-22-128 (20 meters/13.6 meters est. true width of 136 gpt silver with 2 meters of 520 gpt silver) 2

CDH-24-152

  • Large step out along strike of previous drilling.
  • Tests the upper edge of high grade zone near 1775 meter above seal level
  • ~ 200 meters along strike of CDH-23-147 ( 532 gpt silver over 8 meters drilled/4.96 meters est. true width within 219 gpt silver over 28 meters) 3
  • ~ 150 meters up dip of CDH-24-153
  • 347 gpt silver over  5.6 meters drilled/3.36 meters est. true width within 240 gpt silver over 9.0 meters drilled /5.4 meters est. true width.
  • 492 gpt silver over 2.65 meters drilled/1.59 meters est. true width.

The current drilling program is designed to find the strike extent of D-Vein mineralization in preparation of infill drilling and a now fully funded follow up program of 20,000 meters, aimed to delineate a maiden resource expected in late 2024. In addition to the D-Vein, the Company maintains a priority list of new vein targets and known vein extensions all warranting drill testing.

Kootenay's President & CEO, James McDonald states, "We increased the magnitude of step outs on the D-Vein with 100 to 300 meter step outs to great success on the first few holes. These large step outs along strike and down dip are rapidly building volume of mineralized vein. We are very excited to continue stepping out and are preparing to add a drill rig to test high priority targets while one will remain dedicated to step out then infill drilling of D-Vein."

Drill highlights, maps and sections from the project are tabulated on the Company's website at the links below

Click to view the drill plan , long section , and cross sections .

Table 1. D Vein Intercepts from shallow drilling

Hole ID

From
(meters)

To
(meters)

Interval
(meters)

Est. True
width

Silver
gpt

Pb
%

Zn%

Geologic
Intersection

CDH-24-148

92.00

97.00

5.00

2.50

47

0.01

0.01

D-Vein

CDH-24-149

226.50

228.00

1.50

0.75

53

0.01

0.15


CDH-24-150

no

significant

intervals





D Vein at 153-
157.5m

CDH-24-151

123.00

148.50

22.5 *

12.00

72.5

0.02

0.05

D-Vein

Includes

126.00

129.00






Cavern

and

130.50

141.30

10.80

6.16

140

0.04

0.05

D-Vein

Includes

136.00

137.00

1.00

0.57

223

0.03

0.06

D-Vein










Table 2. Highlights of Drill holes Targeting D-Vein Below 1750m elevation

Hole ID

From
(meters)

To
(meters)

Interval
(meters)

Est. True
width

Silver
gpt

Pb
%

Zn%

Geologic
Intersection

CDH-24-152

140.00

170.00

30.00

18.00

83

0.05

0.17

D-Vein System

includes

148.00

157.00

9.00

5.40

240

0.14

0.42

D-Vein System

includes

150.40

156.00

5.60

3.36

347

0.20

0.60

D-Vein

Includes

151.50

154.15

2.65

1.59

492

0.40

1.05

D-Vein

Includes

152.00

153.00

1.00

0.60

539

0.30

1.60

D-Vein

CDH-24-153

275.50

316.00

40.50

12.96

183

0.01

0.22

D-Vein System

includes

300.00

311.00

11.00

3.52

481

0.02

0.68

D-Vein

includes

309.00

310.35

1.35

0.43

920

0.80

3.30

D-Vein

As previously mentioned, results discussed herein represent the first series of holes designed as aggressive step outs along the D-Vein structure in a region where the structure is not visible at surface.  Holes CDH-24-148 to CDH-24-151 successfully intersected the target at shallow depths, above the projected upper horizon of strong mineralization. These holes will provide invaluable information for subsequent drilling targeting high grade mineralization. Holes CDH-24-152 and CDH-24-153 intersected the D Vein at a deeper levels and silver grades returned were correspondingly higher.

The company has completed over 30,000 meters of diamond drilling in 153 holes at Columba since 2019 and intercepted numerous veins with high silver grades and widths indicating excellent resource potential. Prospective veins on the project are hosted within a volcanic caldera setting, the surface extent of mapped veins measuring roughly 4 kilometres by 3 kilometres. Management believes that Columba may be a newly recognized vein district that is nearly entirely preserved from erosion.

A comprehensive list of drill results completed on the Columba Property since 2019 may be viewed here: Columba Drill Results .

Sampling and QA/QC at Columba

All technical information for the Columba exploration program is obtained and reported under a formal quality assurance and quality control ("QA/QC") program. Samples are taken from core cut in half with a diamond saw under the direction of qualified geologists and engineers. Samples are then labeled, placed in plastic bags, sealed and with interval and sample numbers recorded. Samples are delivered by the Company to ALS Minerals ("ALS") in Chihuahua. The Company inserts blanks, standards and duplicates at regular intervals as follows. On average a blank is inserted every 100 samples beginning at the start of sampling and again when leaving the mineral zone. Standards are inserted when entering the potential mineralized zone and in the middle of them, on average one in every 25 samples is a standard. Duplicates are taken in the mineralized intervals at an average 2 duplicates for each hole.

The samples are dried, crushed and pulverized with the pulps being sent airfreight for analysis by ALS in Vancouver, B.C. Systematic assaying of standards, blanks and duplicates is performed for precision and accuracy. Analysis for silver, zinc, lead and copper and related trace elements was done by ICP four acid digestion, with gold analysis by 30-gram fire assay with an AA finish. All drilling reported is HQ core and was completed by Globextools, S.A. de C.V. of Hermosillo, Sonora, Mexico .

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Qualified Persons

The Kootenay technical information in this news release has been prepared in accordance with the Canadian regulatory requirements set out in National Instrument 43-101 (Standards of Disclosure for Mineral Projects) and reviewed and approved on behalf of Kootenay by Mr. Dale Brittliffe, BSc. P. Geol., Vice President, Exploration of Kootenay Silver, is the Company's nominated Qualified Person pursuant to National Instrument 43-101, Standards for Disclosure for Mineral Projects, has reviewed the scientific and technical information disclosed in this news release. Mr. Brittliffe is not independent of Kootenay Silver.

About Kootenay Silver Inc.

Kootenay Silver Inc. is an exploration company actively engaged in the discovery and development of mineral projects in the Sierra Madre Region of Mexico . Supported by one of the largest junior portfolios of silver assets in Mexico , Kootenay continues to provide its shareholders with significant leverage to silver prices. The Company remains focused on the expansion of its current silver resources, new discoveries and the near-term economic development of its priority silver projects located in prolific mining districts in Sonora , State and Chihuahua, State, Mexico , respectively.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

The information in this news release has been prepared as at May 20, 2024 . Certain statements in this news release, referred to herein as "forward-looking statements", constitute "forward-looking statements" under the provisions of Canadian provincial securities laws. These statements can be identified by the use of words such as "expected", "may", "will" or similar terms.

Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by Kootenay as of the date of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Many factors, known and unknown, could cause actual results to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as otherwise required by law, Kootenay expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Kootenay's expectations or any change in events, conditions or circumstances on which any such statement is based.

Cautionary Note to US Investors: This news release includes Mineral Reserves and Mineral Resources classification terms that comply with reporting standards in Canada and the Mineral Reserves and the Mineral Resources estimates are made in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (" NI 43-101 "). NI 43-101 is a rule developed by the Canadian Securities Administrators that establishes standards for all public disclosure an issuer makes of scientific and technical information concerning mineral projects. These standards differ significantly from the requirements adopted by the U.S. Securities and Exchange Commission (the " SEC "). The SEC sets rules that are applicable to domestic United States reporting companies. Consequently, Mineral Reserves and Mineral Resources information included in this news release is not comparable to similar information that would generally be disclosed by domestic U.S. reporting companies subject to the reporting and disclosure requirements of the SEC. Accordingly, information concerning mineral deposits set forth herein may not be comparable with information made public by companies that report in accordance with U.S. standards.

________________________________

1 Previously released December 7, 2023. Drilled width with estimated true width 65 to 80% of drilled.

2 Previously released September 8, 2022. Drilled width with estimated true width 65 to 85% of drilled.

3 Previously released December 14, 2023. Drilled width with estimated true width 45 to 50% of drilled.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/drilling-dramatically-increases-strike-length-of-d-vein-with-highs-to-920-gpt-silver-and-4-1-lead-zinc-at-columba-high-grade-silver-project-302150753.html

SOURCE Kootenay Silver Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2024/21/c8788.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
122.5 m at 1.42% Li2O and 71.4 m at 1.57% Li2O at CV5

122.5 m at 1.42% Li2O and 71.4 m at 1.57% Li2O at CV5

May 16, 2025 – Sydney, Australia

Highlights
  • Continued strong lithium mineralization over wide intervals from infill drilling at CV5.
    • 122.5 m at 1.42% Li 2 O , including 35.8 m at 2.15% Li 2 O (CV24-405).
    • 71.4 m at 1.57% Li 2 O , including 14.2 m at 3.15% Li 2 O (CV24-435).
    • 68.7 m at 1.56% Li 2 O and 22.5 m at 1.04% Li 2 O (CV24-414).
    • 74.9 m at 1.28% Li 2 O , including 28.1 m at 2.28% Li 2 O (CV24-423A).
    • 53.0 m at 1.22% Li 2 O , including 25.0 m at 1.65% Li 2 O (CV24-450).
  • The focus of the 2024 winter drilling at CV5 was to support an upgrade in mineral resource confidence, from the inferred category to the indicated category, targeting release in Q3 2024 inclusive of a maiden CV13 resource.
  • Multiple holes remain to be reported targeting the newly discovered high-grade zone at CV13, with the Company to report the assay results as soon as they are received in the coming weeks.
  • 38,887 m (111 holes) remain to be reported from the 2024 winter drill program – 27,611 m (67 holes) at CV5, and 11,276 m (44 holes) at CV13.

Patriot Battery Metals Inc. (the "Company" or "Patriot") (TSX: PMET) (ASX: PMT) (OTCQX: PMETF) (FSE: R9GA) is pleased to announce the next batch of core assay results for drill holes completed in 2024 at the CV5 Spodumene Pegmatite. The Corvette Property (the "Property" or "Project"), wholly owned by the Company, is located in the Eeyou Istchee James Bay region of Quebec . The CV5 Spodumene Pegmatite, with a maiden mineral resource estimate ("MRE") of 109.2 Mt at 1.42% Li 2 O inferred 1 , is situated approximately 13.5 km south of the regional and all‑weather Trans-Taiga Road and powerline infrastructure.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
American Creek's JV Partner Tudor Gold Commences 2024 Exploration Drill Program at Treaty Creek, Golden Triangle, British Columbia

American Creek's JV Partner Tudor Gold Commences 2024 Exploration Drill Program at Treaty Creek, Golden Triangle, British Columbia

American Creek Resources Ltd. (TSXV: AMK) (OTCQB: ACKRF) ("the Corporation" or "American Creek") is pleased to announce that crews from JV partner Tudor Gold are on site preparing camp and drill locations for the upcoming 2024 exploration program at the flagship Treaty Creek Project, located in the Golden Triangle of Northwest British Columbia. Two diamond drills were mobilized to the project on May 7th and 8th and drilling commenced on May 9th.

Phase 1 of the 2024 exploration program is expected to consist of approximately 10,000 meters (m) of diamond drilling at the Goldstorm Deposit. The primary objective of the Phase 1 drill program is to expand and upgrade the recently released Mineral Resource Estimate (news release dated April 8, 2024). Several drill holes have been designed as step-out drilling to the high-grade Supercell One (SC-1) system identified in 2023 (news release dated February 1, 2024). Supercell One is a gold dominant, quartz-sulphide, breccia-hosted structural corridor open to the northwest, north and east.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Falco Announces Resignation of Board Member

Falco Announces Resignation of Board Member

Falco Resources Ltd. (TSX-V: FPC) ( "Falco" or the " Corporation" ) announced today that Mr. Claude Dufresne has resigned as a member of the Board of Directors so that he may focus his efforts on other professional duties.

The Board of Directors would like to thank Mr. Dufresne for his contribution over the past few years and wish him well in his future endeavors.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Bold Options Claims in Ring of Fire Region

Bold Options Claims in Ring of Fire Region

Bold Ventures Inc. (TSXV:BOL) (the "Company" or "Bold") is pleased to announce that it has signed an option agreement (the "Agreement") to option a 100% interest in two claim groups (the "Optioned Claims") to an arms-length party (the "Optionee"). The claims are located in the Ring of Fire Region. The Optioned Claims were staked during a regional airborne Electromagnetic and Magnetic survey flown in 2013 for Bold Ventures and its co-Venturer, a subsidiary of Dundee Resources. The survey resulted in over 14 claim groups being staked at various times over two campaigns. The Optioned Claims have a combined area of approximately 2,595 acres (1,050 hectares) and comprise approximately 90 claim units. The Optioned Claims have seen very little exploration work in the past

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
WESTERN COPPER AND GOLD ANNOUNCES VOTING RESULTS FROM ANNUAL SHAREHOLDERS' MEETING

WESTERN COPPER AND GOLD ANNOUNCES VOTING RESULTS FROM ANNUAL SHAREHOLDERS' MEETING

western copper and gold corporation ("Western" or the "Company") (TSX: WRN) (NYSE American: WRN) announces the voting results from the Company's Annual General and Special Meeting ("AGM") held on June 27, 2024.

Western Copper and Gold Corporation logo (CNW Group/Western Copper and Gold Corporation)

A total of 101,875,249 common shares were represented at the AGM, representing 51.92% of the votes attached to all outstanding common shares as at the record date.

Shareholders voted in favour of setting the number of directors at seven (7) and elected all directors, as follows:

Director

Votes For

% For

Votes Withheld

% Withheld

Robert Chausse

90,608,768

99.84 %

165,930

0.16 %

Tara Christie

82,647,749

90.20 %

8,979,661

9.80 %

Sandeep Singh

91,295,444

99.64 %

331,966

0.36 %

Raymond Threlkeld

90,876,101

98.85 %

1,018,642

1.11 %

Michael Vitton

87,843,574

95.87 %

3,783,836

4.13 %

Bill Williams

83,566,754

91.20 %

8,060,656

8.80 %

Klaus Zeitler

83,576,626

91.21 %

8,050,785

8.79 %

Shareholders also approved:  (i) the appointment of PricewaterhouseCoopers LLP as auditors of the Company and authorized the directors to set their remuneration, (ii) unallocated stock options under the Company's stock option plan, (iii) unallocated rights under the Company's deferred share unit plan, (iv) unallocated rights under the Company's restricted share unit plan.

The Company's report of voting results will be available on SEDAR ( www.sedar.com ), EDGAR ( www.sec.gov/edgar.shtml ), and on the Company's website.

ABOUT western copper and gold corporation

western copper and gold corporation is developing the Casino Project, Canada's premier copper-gold mine in the Yukon Territory and one of the most economic greenfield copper-gold mining projects in the world.

The Company is committed to working collaboratively with our First Nations and local communities to progress the Casino project, using internationally recognized responsible mining technologies and practices.  For more information, visit www.westerncopperandgold.com .

On behalf of the board,

"Sandeep Singh"

Sandeep Singh
Chief Executive Officer
western copper and gold corporation

SOURCE western copper and gold corporation

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2024/27/c2084.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
FALCO ANNOUNCES CLOSING OF FIRST TRANCHE OF BROKERED PRIVATE PLACEMENT

FALCO ANNOUNCES CLOSING OF FIRST TRANCHE OF BROKERED PRIVATE PLACEMENT

TSX.V - FPC

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Forte Minerals Corp. Closes Oversubscribed Private Placement Offering

Forte Minerals Corp. Closes Oversubscribed Private Placement Offering

(Not for distribution to United States newswire services or for dissemination in the United States of America)

Forte Minerals Corp. ("Forte" or the "Company") (CSE:CUAU)(OTCQB:FOMNF)(Frankfurt:2OA), is pleased to announce the closing of its previously announced non-brokered private placement (the "Offering") (see press release dated June 5, 2024). The Offering was initially set for 7,500,000 units but, due to high demand, was oversubscribed, resulting in the issuance of 8,953,000 units at a price of CAD $0.20 per unit for aggregate gross proceeds of CAD $1,790,600

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Aston Bay Announces Planned Exploration Program at its Epworth Sediment Hosted Copper-Silver-Zinc-Cobalt Project, Nunavut, Canada

Aston Bay Announces Planned Exploration Program at its Epworth Sediment Hosted Copper-Silver-Zinc-Cobalt Project, Nunavut, Canada

Airborne geophysics, structural mapping, and sampling to define drill targets

Aston Bay Holdings Ltd. (TSX-V:BAY)(OTCQB:ATBHF) (the "Company" or "Aston Bay") is pleased to announce the proposed summer 2024 exploration program at its Epworth sediment hosted copper-silver-zinc-cobalt project located 80 kilometres ("km") southeast of Kugluktuk in Nunavut, Canada

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×